Thulium laser with growth-factor serum (with or without LED) for androgenetic hair loss

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares three treatment approaches for adults with androgenetic alopecia: thulium laser alone, thulium laser with a topical growth-factor serum, and thulium laser with growth-factor serum combined with LED phototherapy. Participants are adults aged 18 and over without scarring alopecia or major contraindications and will receive treatments and scheduled follow-up visits at a single center. Outcomes include objective hair measurements and patient-reported hair and scalp satisfaction to capture both clinical and patient-side effects. The protocol excludes pregnant or breastfeeding women, recent resurfacing procedures, metallic head implants, significant scalp wounds, and other specified contraindications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women aged 18 and over
* Good general health, no relevant previous illnesses
* Presence of an AGA
* Cognitive ability and willingness to give consent (informed consent)
* Be willing and able to attend follow-up visits

Exclusion Criteria:

* Age \< 18 years
* Pregnant or breastfeeding women
* Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
* Significant scarring of the region to be treated
* Significant open wounds or lesions in the region to be treated
* Metallic implants in the head region
* Mental illnesses (psychoses, body perception disorders)
* Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
* Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period
* Tendency to excessive scarring
* Lack of informed consent and/or data protection declarations

Where it's running

• University Medical Center Hamburg-Eppendorf
  Hamburg, Free and Hanseatic City of Hamburg, Germany Recruiting

Study contacts

• Study coordinator: Lynhda Nguyen, Dr. med.
• Email: l.nguyen@uke.de
• Phone: +49 (0)40 7410 54289

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exosome therapy for male pattern baldness

  This trial tests whether injecting hUCMSC-derived exosomes into the scalp can promote hair regrowth in men with androgenetic alopecia, compared with a placebo.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07693244

• Multi-omics view of androgenetic alopecia in scalp tissue

  This study tests a multi-omics approach to understand hair follicle biology in men with androgenetic alopecia by comparing affected and healthy scalp tissue.

  Recruiting The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07603544

• VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia

  This trial tests if VENEZE peptide hair serum helps adults with androgenetic alopecia grow thicker, denser hair compared with 2% topical minoxidil.

  Recruiting at 2 sites Institute of Dermatology, Thailand · Bangkok, Bangkok and 1 other locations · NCT07536100

• Topical Lactobacillus reuteri for hair loss due to androgenetic alopecia

  This trial will test whether applying a topical Lactobacillus reuteri solution can increase hair count and improve hair quality in adults (18–60) with androgenetic alopecia over 12 months.

  Recruiting Phase 2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07370519

• OLX72021 for men with male-pattern hair loss

  This research will test whether OLX72021 is safe and may help men aged 18 to 59 with mild to moderate male-pattern hair loss.

  Recruiting Phase 1/2 Olix Pharmaceuticals, Inc. · Botany, New South Wales and 7 other locations · NCT07327359

• ABS-201 for improving hair growth in healthy adults and people with androgenetic alopecia

  This trial will test whether ABS-201 is safe and helps hair grow in healthy adults and in men and women with androgenetic alopecia.

  Recruiting at 5 sites Phase 1/2 Absci Pty Ltd. · Sydney, New South Wales and 4 other locations · NCT07317544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.